All articles by CE – Page 7
-
NewsGilead acquires potential first-in-class T cell engager in $2bn deal with Ouro Medicines
T cell engager gamgertamig could redefine standard of care for immune-mediated diseases.
-
NewsNanoparticle-exosome innovation could enhance cell therapy manufacturing
Novel, end-to-end process improves all four steps of exosome production simultaneously, supporting the design of more effective treatments.
-
NewsBMS wins dual immunotherapy-first approvals in classical Hodgkin Lymphoma
Expanded EU and US approvals for Bristol Myers Squibb’s Opdivo (nivolumab) position combination therapy as frontline option for the common blood cancer.
-
NewsNovartis strengthens its breast cancer pipeline with $3bn Synnovation acquisition
Deal to help address the significant unmet need in HR+/HER2- breast cancer and other advanced solid tumours.
-
NewsPennsylvania to house new actinium-225 manufacturing facility
Construction of TerraPower Isotopes’ cGMP facility increases its production capacity for the rare isotope, helping to boost global access to targeted alpha therapies.
-
NewsSandoz partners with Samsung Bioepis to accelerate biosimilar pipeline
New licensing, development and commercialisation agreement could expand Sandoz’s pipeline by to up to 32 assets.
-
NewsUpcycled plastic could facilitate production of Parkinson’s drug
Bioengineered E.coli provide an eco alternative to creating L-DOPA from terephthalic acid, suggests study.
-
NewsEli Lilly doubles down on supply chain investment in Asia
Pharma giant to strengthen manufacturing capabilities in Japan and add capacity in China for its first oral GLP-1 therapy candidate, orforglipron.
-
NewsSana's islet cell transplant therapy shows early promise in type 1 diabetes
Biotech company’s long-term data demonstrated hypoimmune (HIP)-modified islet transplantation without immunosuppression in type 1 diabetes.
-
NewsNeuro-specialist Lundbeck hires new AI lead
New recruit brings over 15 years of leadership experience to the brain health-focused biopharmaceutical company.
-
NewsChiesi and Bespak further collaboration to advance UK production of low carbon inhalers
Partnership increases industrial scale of low carbon pressurised metered dose inhalers (pMDIs), accelerating pharma’s transition to a more sustainable option.
-
NewsGSK grants rare disease firm Alfasigma rights to linerixibat for $690m
Licence agreement with the Italy-based pharma company to advance GSK’s ambitions in rare disease.
-
NewsStudy optimises automated de-bagging in aseptic manufacturing
Mechanical design improvements greatly enhanced success rate during primary de-bagging for double-bag products.
-
NewsFDA revises PK study approach in new biosimilar draft guidance
Sandoz is also adjusting its global strategy by recruiting Armin Metzger as President of Biosimilar Development, Manufacturing & Supply.
-
NewsVinay Prasad to exit CBER as FDA group director
US agency is set to see another new face take the helm, following Dr Prasad’s departure at the end of April.
-
NewsCSL breaks ground on $1.5bn Illinois plasma therapy facility expansion
US manufacturing investment forms part of the firm’s efforts to increase its domestic presence and support its supply network.
-
NewsCleanroom air quality not impaired by height-adjustable furniture
Incorporating ergonomic improvements into pharmaceutical cleanrooms may not negatively impact particle contamination control, according to a new study.
-
NewsServier deepens rare oncology commitment with $2.5bn Day One acquisition
The deal aligns with the biopharma company’s goal of expanding its oncology pipeline by the end of the decade.
-
NewsNanofiltration study highlights next-generation water treatment process
The technology could offer defect-free, high-efficiency ceramic-based water filtration through ultra-precise control of nanopores and surface structure.
-
NewsBiogen/Stoke’s zorevunersen hailed as potential first disease-modifying drug for rare epilepsy
Clinical readout for Dravet syndrome trial part of the collaboration the companies signed in 2025.